ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VCEL
MESO (51) BCRX (67) COAG (59) VIR (40) ⌘ Pro Terminal →

Vericel Corporation (VCEL) — RQD Stock Rating Cockpit

$40.51 +0.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $40.48

Vericel Corporation (VCEL) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.06B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VCEL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Vericel Corporation (NASDAQ: VCEL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $40.51 (+0.62% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, VCEL ranks #182 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VCEL compare to MESO and BCRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VCEL carries a Roarable D+ (58/100 RQD), trailing P/E of 133.0x, gross margin of 74.4%, and ROIC of 3.4%. By comparison, MESO (Mesoblast Limited) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.97B) and BCRX (BioCryst Pharmaceuticals Inc.) posts a C+ grade (67/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.16B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VCEL?
▼

Per VCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000887359), Vericel Corporation generated $276.3M in revenue (+16.5% YoY), $16.5M in net income, and $24.7M in free cash flow against $488.0M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $40.48 (-0.08%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510058
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C+
Cash (14)Whales (9)SEC (18)Macro (9)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
$52 Bull$41 Base$32 Bear
📬 FREE VCEL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCEL)Realized 20D OHLCV Swing Band: ±8.7%
Deterministic 5-Pillar Attribution (58/100 Composite)
🔍 WHY VCEL SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (31% of score)

Altman Z-Score 9.94 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 9% FCF Margin ($24.7M FCF) & 74.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
50
Grade C-$40.30+0.7% Next Q
Q2 (-2Q)
53
Grade C-$40.58+6.6% Next Q
Q3 (-1Q)
55
Grade C$43.27-6.4% Next Q
Current
58
Grade D+$40.51+0% Hist 90D α
Trajectory: C- (50) → D+ (58)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VCEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, VCEL faces multiple-compression risk if 133.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($40.54) or 200D SMA ($38.69) invalidates the momentum regime and cuts Target Base ($40.51) toward Bear Floor ($31.60).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VCEL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 58%NO 42%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
9.94>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE57% OF RANGE
L: $29$40.51H: $49
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (74.4% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on VCEL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

3.4% ROIC with 74.4% gross margin and 1.13% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 9.94 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (43)

17/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like VCEL
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Priced at 133x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VCEL)

  • ✓Walkthrough of VCEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.02%🛡️ HOLDING TREND SUPPORT
2026-11-03O $42.91H $42.91L $40.26C $40.51VOL 598.8K
RES: $43.29SUP: $40.23SMA50: $40.54SMA200: $38.69
$50.54$45.48$40.42$35.35$30.29RES $43.29SUP $40.23$40.512026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCEL Butterfly Map → + Track VCEL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCEL)

Health Care Rank #182 of 1015 ⚔️ MESO vs VCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCEL vs. MESO, BCRX, COAG, VIR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vericel Corporation (VCEL) ranks #182 by composite RQD confidence (58/100, grade D+) and #247 by equity capitalization ($2.06B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with VCEL at 58/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VCEL ACTIVE
Vericel Corporation
D+ 58/100 133.0x 74.4% 3.4% +0.62% $2.06B Benchmark Subject
MESO
Mesoblast Limited
D 51/100 — — — -4.09% $1.97B /meso-vs-vcel →
BCRX
BioCryst Pharmaceuticals Inc.
C+ 67/100 8.3x — 85.0% -2.66% $2.16B /bcrx-vs-vcel →
COAG
Hemab Therapeutics Holdings Inc.
C- 59/100 — — — -0.65% $1.94B /coag-vs-vcel →
VIR
Vir Biotechnology Inc.
D- 40/100 — 96.0% -35.0% -2.65% $1.93B /vir-vs-vcel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000887359 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vericel Corporation (VCEL) reported GAAP revenue of $276.3M (+16.5% vs. FY2024 revenue of $237.2M , and +39.9% cumulative change since FY2023) , GAAP net income of $16.5M, operating cash flow of $51.9M, and free cash flow of $24.7M (+525.9% YoY). On the balance sheet, VCEL closed FY2025 with $488.0M in total assets against $0 in total debt (Altman Z-Score: 9.94, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $276.3M $16.5M $51.9M $24.7M $488.0M —
FY2024 (FY) 2024-12-31 $237.2M $10.4M $58.2M -$5.8M $432.7M —
FY2023 (FY) 2023-12-31 $197.5M -$3.2M $35.3M $35.3M — —

3. VCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vericel Corporation (NASDAQ: VCEL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $40.51 (+0.62% 1D, market cap $2.06B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, VCEL ranks #182 in composite RQD confidence.

How does VCEL compare to MESO and BCRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VCEL carries a Roarable D+ (58/100 RQD), trailing P/E of 133.0x, gross margin of 74.4%, and ROIC of 3.4%. By comparison, MESO (Mesoblast Limited) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $1.97B) and BCRX (BioCryst Pharmaceuticals Inc.) posts a C+ grade (67/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.16B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCEL?

Per VCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000887359), Vericel Corporation generated $276.3M in revenue (+16.5% YoY), $16.5M in net income, and $24.7M in free cash flow against $488.0M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

VCEL last traded at $40.51 (+0.62% on volume of 684,385 shares), positioning the stock -0.07% below its 50-day simple moving average ($40.54) and +4.70% above its 200-day simple moving average ($38.69). Across its 52-week range of $28.95 to $49.32, VCEL sits at the 56.8% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.7% ($36.99 to $44.03).

Direct Sub-Reports: VCEL RQD Cockpit VCEL 12M Forecast VCEL Earnings & Move VCEL Dividends & DRIP VCEL Insiders & 13F VCEL Whale Options VCEL Profit Sankey VCEL News & Why
ROARABLE RATING BRIEF • RQD 58/100 (D+) ✓ SEC XBRL & RQD VERIFIED

VCEL — Vericel Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vericel Corporation (VCEL) earns a live Roarable RQD composite score of 58/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $40.51 (+0.62% 1D, market capitalization $2.06B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 3.4%, gross margin of 74.4%, operating margin of 4.0%, and free cash flow yield of 1.13%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.94, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vericel Corporation (VCEL) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vericel Corporation (VCEL) reported $276.3M in annual revenue (up from $237.2M in FY2024, +16.5% YoY) and $16.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($197.5M revenue, -$3.2M net income) through FY2025, VCEL scaled operating cash flow to $51.9M and free cash flow to $24.7M, backed by $488.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 58/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 1.13% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $28.95 – $49.32 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 133.0x trailing P/E and 61.4x EV/EBITDA against 4.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is "NONE" and butterfly_links is empty.

  • Key Question #1: Can VCEL sustain or expand its 4.0% operating margin and 3.4% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $276.3M and free cash flow of $24.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VCEL's 111.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VCEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vericel Corporation (VCEL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VCEL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VCEL Bull vs. Bear Conversation Board — What's Your Call at $40.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VCEL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VCEL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $46.30 (+15.0%)
📌 Pinned Debate

Revenue rose from $197.5M to $276.3M with net income turning to $16.5M and a forensic balance sheet scoring 18 / 20 on Altman Z 9.94 an

Revenue rose from $197.5M to $276.3M with net income turning to $16.5M and a forensic balance sheet scoring 18 / 20 on Altman Z 9.94 and Piotroski F 8/9.. When you look under the hood at VCEL, Fundamental Cash Engine is 14/20 with 74.4% gross margins and 3.4% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (9/20) has been quietly accumulating below $49.32. My 12M target is $46.30.

EarningsSniper 🐂 BULL

@MeanReversion_88 Shorting a 9/20 institutional whale-flow stock at $40.26 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $30.60 (-24.0%)
Spot @ $40.26

At a trailing P/E of 133 and EV/EBITDA of 61.4 against ROIC of 3.4% and FCF yield of 1.13%, the valuation leaves little margin for exec

At a trailing P/E of 133 and EV/EBITDA of 61.4 against ROIC of 3.4% and FCF yield of 1.13%, the valuation leaves little margin for execution error.. Look at the math on VCEL: paying 133.0x trailing P/E for 3.4% ROIC and 4.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $35.43 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%